Pfizer sues Metsera for backing Novo Nordisk's higher $8.5B offer

Pfizer sued Metsera and Novo Nordisk in Delaware court, alleging Metsera breached their $7.3 billion merger agreement by accepting Novo's higher $8.5 billion offer as superior. Pfizer seeks a temporary restraining order to prevent Metsera from terminating the agreement and wants the November 13 shareholder vote to proceed. Novo calls Pfizer's claims "meritless" and will defend vigorously. The dispute centers on Metsera's obesity drug pipeline worth potentially $5 billion in sales.